Generated by AI
Cellectis S.A. ADR is a clinical-stage biotechnology company focused on gene editing and cell therapy. Cellectis develops gene-edited, off-the-shelf immunotherapies designed to target cancer, with a portfolio centered on allogeneic CAR T-cell product candidates and other engineered cell and gene therapy programs. Its current work spans hematologic cancers and select solid tumor indications, using proprietary genome-editing technology to create therapies that can be manufactured in a standardized form. The company also advances gene-edited hematopoietic stem and progenitor cell research for additional therapeutic applications. Based in Paris, France, Cellectis serves the biopharmaceutical sector by contributing specialized platforms and product candidates that support the broader development of next-generation cancer and gene therapy treatments.
Website8, rue de la Croix Jarry
Paris, 75013
France
The latest articles about CLLS.
Summary of Sep 14's posts. Generated by AI.
Summary of Mar 14's posts. Generated by AI.
Summary of Oct 16's posts. Generated by AI.
Investors talking about CLLS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.